Abstract
This research was funded by a Wellcome Trust (grant RG76641) and Isaac Newton Trust grant (Grant RG70368). GF was also supported by a Wellcome ISSF award (204796/Z/16/Z). PS was supported by the Autism Research Trust and the Wellcome Trust. SBC received funding from the Wellcome Trust 214322/Z/18/Z. In addition, SBC received funding from Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777394. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. SBC also received funding from the Autism Research Trust, SFARI, the Templeton World Charitable Fund, SFARI, and the NIHR Cambridge Biomedical Research Centre. The research was supported by the (U.K.) National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
